64
Participants
Start Date
October 24, 2019
Primary Completion Date
January 31, 2024
Study Completion Date
January 31, 2024
Emtricitabine / Tenofovir Disoproxil Oral Tablet 200/300 mg
Following Phase I lead-in, all participants will continue PrEP with fixed dose combination daily oral F/TAF substituting for F/TDF in Phase II. Participants will continue to receive PrEP in accordance with standardized comprehensive methods of prescribing, which includes risk reduction counseling, adherence counseling, and clinical assessments with safety monitoring, as well as HIV and STI screening. Participants will receive daily adherence-supporting text message reminders through 12 weeks after F/TAF initiation.
Emtricitabine Tenofovir Alafenamide 200/25 mg
Following Phase I lead-in, all participants will continue PrEP with fixed dose combination daily oral F/TAF substituting for F/TDF in Phase II. Participants will continue to receive PrEP in accordance with standardized comprehensive methods of prescribing, which includes risk reduction counseling, adherence counseling, and clinical assessments with safety monitoring, as well as HIV and STI screening. Participants will receive daily adherence-supporting text message reminders through 12 weeks after F/TAF initiation
UC San Diego AntiViral Research Center (AVRC), San Diego
University of California, San Diego
OTHER